OctreoTher(TM): Ongoing early clinical development of a somatostatin- receptor-targeted radionuclide antineoplastic therapy

Digestion

Volumn 62, Issue SUPPL. 1, 2000, Pages 69-72

  Smith, M Charles ^a   Liu, Jingou ^a   Chen, Tianling ^a   Schran, Horst ^a   Yeh, Ching Ming ^a   Jamar, François ^b   Valkema, Roelf ^d   Bakker, Willem ^d   Kvols, Larry ^c   Krenning, Eric ^d   Pauwels, Stanislas ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d Bldg 419 ^*

Author keywords

Breast cancer; Clinical studies; DOTATOC; Neuroendocrine tumors; OctreoTher(TM); Peptide radiotherapy; Small cell lung cancer; Somatostatin receptor; Yttrium 90

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANTINEOPLASTIC AGENT; OCTREOTHER; OCTREOTIDE[3 TYROSINE]; PENTETREOTIDE; YTTRIUM 90; (DOTA(0) PHE(1) TYR(3))OCTREOTIDE; (DOTA(0)-PHE(1)-TYR(3))OCTREOTIDE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; INDIUM; OCTREOTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; YTTRIUM;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG SAFETY; DRUG SCREENING; DRUG TOLERANCE; HUMAN; METASTASIS; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SMALL CELL CARCINOMA; ANIMAL; BREAST TUMOR; FEMALE; LUNG TUMOR; MALE; METABOLISM; MOUSE; NEOPLASM; NEUROENDOCRINE TUMOR; NUDE MOUSE; RADIATION RESPONSE; REVIEW;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, SMALL CELL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; INDIUM RADIOISOTOPES; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; NEOPLASMS; NEUROENDOCRINE TUMORS; OCTREOTIDE; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; YTTRIUM RADIOISOTOPES;

EID: 0033839270     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051858     Document Type: Conference Paper

References (14)

1. 90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med 1998;25:668-674.
2. Hammond PJ, Wade AF, Gwilliam ME, et al: Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer 1993;67:1437-1439.
3. Mogensen CE, Solling K: Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids. Scand J Clin Lab Invest 1977;37:477-486.
4. Maher J: Section 6: Diseases of the kidney and urinary tract. Part 8: Radiation Nephropathy; in Masary SG, Glassock RJ (eds): Textbook of Nephrology. Baltimore, Williams & Wilkins, 1989.
5. 3]-octreotidc: The Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 1993;20: 716-731.
6. Kwekkeboom DJ, Kho GS, Lamberts SJ, et al: The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 1994;21: 1106-1113.
7. 111In]pentetreotide, a radiolabelled somatostatin analogue. Br J Cancer 1994;69:762-766.
8. 111In-DPTA octreotide scintigraphy. Eur J Cancer 1995;31A:184-188.
9. Bootsma AH, van Eijck CHJ, Schouten KK, et al: Somatostatin receptor-positive primary breast tumors: Genetic, patient and tumor characteristics. Int J Cancer 1993;54:357-362.
10. Van Eijck CHJ, Krenning EP, Bootsma A, et al: Somatostatin receptor scintigraphy in primary breast cancer. Lancet 1994;343:640-643.
11. Evans AA, Crook T, Laws SAM, et al: Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. Br J Cancer 1997;75:798-803.
12. Otte A, Hermann R, Heppler A, et al: Yttrium-90 DOTATOC: First clinical results. Eur J Nucl Med 1999;26:1439-1447.
13. Otte A, Jermann E, Behe M, et al: DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997;24: 792-795.
14. Otte A, Mueller-Brand J, Dellas S, et al: Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998;351:417.